Connect with us

Health

ctDNA May Be Reliable Predictor of Outcomes with First-Line Immunotherapy for Melanoma – Cancer Network

Pretreatment circulating tumor DNA was found to be a reliable indicator of patient outcome for those with metastatic melanoma in the first-line immune checkpoin…

Published

on

post featured image

Pretreatment circulating tumor DNA (ctDNA) is a reliable indicator of patient outcome for patients with metastatic melanoma in the first-line immune checkpoint inhibitor (ICI) treatment setting, but not in the second-line setting, especially in those pretreated with BRAF/MEK inhibitors, according to study findings published in Clinical Cancer Research.1
Our results indicate that it is necessary to carefully consider context when implementing biomarkers, senior author Elin Gray, PhD, an associat…

Click here to view the original article.

You might also like ...

COVID-19 pandemic has led to a decrease in hospital-wide HCV testing – News-Medical.Net
post featured image
Just over $600M a year goes to malaria R&D. Can COVID-19 change that? – Devex
post featured image
Digital Breast Tomosynthesis on Track to Replace Digital Mammography – Diagnostic Imaging